Age-Related SarcopeniaHANDGAGESNCT05060874
Gripwise® Versus JAMAR®
An observational study of Age-Related Sarcopenia, run by University Hospital, Caen at 1 site in France.
Trial summary
It is recommended to screen ageing patients for sarcopenia, due to the increased risk of morbimortality if detected positive. According to the consensus of the European Working Group on Sarcopenia in Older People, the diagnosis of sarcopenia is based, among other things, on grip strength measurement. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Age-Related Sarcopenia
- How many people
- 348 participants
- Where
- 1 siteFrance
- Study dates
- 1 Sep 2021to 18 Nov 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: aged inpatients hospitalized in CAEN University Hospital
Who may be able to join
- men and women aged 65 or over
- affiliated to a health insurance
- Francophone.
Who cannot join
- - refusal to participate
- unable to communicate
- unable to use both hands (dominant and non-dominant)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparison of Gripstrength Assessment Between the Gripwise® and JAMAR® Dynamometers in Elderly Inpatients
It is recommended to screen ageing patients for sarcopenia, due to the increased risk of morbimortality if detected positive. According to the consensus of the European Working Group on Sarcopenia in Older People, the diagnosis of sarcopenia is based, among other things, on grip strength measurement.
Our study will compare the performance of the new GRIPWISE digital device with the mechanical dynamometer JAMAR, the gold standard currently used to assess the grip strength. We propose to evaluate it in an elderly hospitalized population where the prevalence of sarcopenia is likely to be high due to the high prevalence of various chronic illness, notably oncological and cardiological ones.
This cross-sectional study will include 348 patients.
- Conditions
- Age-Related Sarcopenia
- Keywords
- aged, inpatients, hand strength
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| single group | gripwise or jamar will be randomly assessed first |
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparison between Jamar® and Gripwise® values for grip strength measurement
Intra-class correlation between the best values obtained with each device
Measured: day1
Secondary outcomes (4)
comparison according to the patient's position
correlations of dynamometer measurements between patients assessed in the sitting or lying position
Measured: day1
number of attempt to reach the maximum value
Comparison of the three measurements obtained for each patient with each device
Measured: day1
factors influencing detected weakness
significant difference in the rate of women detected as weak with a handgrip <16kg and men <27kg, between the different reasons for hospitalisation, the number of days of hospitalisation, and between the different chronic cancerous and non-cancerous pathologies (Updated Charlson Comorbidity Index), the age groups 65-79 years and ≥80 years
Measured: day1
satisfaction using the devices
rate of patients finding one of both device easier to use
Measured: day1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Sep 2021
- Study start1 Sep 2021
- Primary completion1 Sep 2021
- Study completion18 Nov 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Age-Related SarcopeniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 348 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Caen
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Bérengère, University Hospital, Caen
- Investigators
- Bérengère Beauplet, MD, Principal investigator, Caen UH
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05060874
- Sponsor's protocol ID
- 2021-A00927-34
- Acronym
- HANDGAGES
- Status last verified
- Nov 2021
- First submitted
- 22 Sep 2021
- Last updated
- 30 Nov 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 30 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Gripstrength Assessment Between the Gripwise® and JAMAR® Dynamometers in Elderly Inpatients
- ClinicalTrials.gov ID
- NCT05060874
- Acronym / sponsor ID
- HANDGAGES / 2021-A00927-34
- Conditions
- Age-Related Sarcopenia
- Keywords
- aged, inpatients, hand strength
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 348 participants (actual)
- Lead sponsor
- University Hospital, CaenUniversity, hospital or other
- Study start
- 1 Sep 2021 (actual)
- Primary completion
- 1 Sep 2021 (actual)
- Study completion
- 18 Nov 2021 (actual)
- First posted
- 29 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It is recommended to screen ageing patients for sarcopenia, due to the increased risk of morbimortality if detected positive. According to the consensus of the European Working Group on Sarcopenia in Older People, the diagnosis of sarcopenia is based, among other things, on grip strength measurement.
Our study will compare the performance of the new GRIPWISE digital device with the mechanical dynamometer JAMAR, the gold standard currently used to assess the grip strength. We propose to evaluate it in an elderly hospitalized population where the prevalence of sarcopenia is likely to be high due to the high prevalence of various chronic illness, notably oncological and cardiological ones.
This cross-sectional study will include 348 patients.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| single group | – | –gripwise or jamar will be randomly assessed first |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- aged inpatients hospitalized in CAEN University Hospital
Key inclusion criteria (3 listed)
- men and women aged 65 or over
- affiliated to a health insurance
- Francophone.
Key exclusion criteria (3 listed)
- - refusal to participate
- unable to communicate
- unable to use both hands (dominant and non-dominant)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Comparison between Jamar® and Gripwise® values for grip strength measurement
Time frame: day1
Intra-class correlation between the best values obtained with each device
4 secondary outcomes
comparison according to the patient's position
Time frame: day1
number of attempt to reach the maximum value
Time frame: day1
factors influencing detected weakness
Time frame: day1
satisfaction using the devices
Time frame: day1
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Nov 2021.
- Individual participant dataSharing planned: Undecided
Related trials for Age-Related Sarcopenia
Recruiting
Effects of Rehabilitative Exergame Training on Foot Muscle Activity, Balance, and Mobility in Older Adults
Aging, Foot Muscle Dysfunction
RecruitingPhase 1/2
CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy
Age-related Muscle Decline
Active, not recruiting
AI-Guided Sarcopenia Risk Assessment and Detection
Sarcopenia, Age-related Muscle Loss
Recruiting
Multi-organ Responses to CHronic Physical Activity and INactivity
Sedentary Behavior, Metabolic Syndrome
Recruiting
Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune)
Muscle Atrophy, Age-Related Sarcopenia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bérengère Beauplet, MD principal investigator
Caen UH
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Age-Related Sarcopenia, run by University Hospital, Caen at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Comparison between Jamar® and Gripwise® values for grip strength measurement (time frame: day1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2021; AzTrials last refreshed its copy on 28 Oct 2026.